HRT Financial’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-6,616
Closed -$536K 3113
2021
Q4
$536K Buy
+6,616
New +$567K ﹤0.01% 1696
2021
Q3
Sell
-11,926
Closed -$1.18M 3282
2021
Q2
$1.18M Sell
11,926
-6,796
-36% -$593K 0.01% 913
2021
Q1
$1.56M Sell
18,722
-21,354
-53% -$2.01M 0.02% 759
2020
Q4
$3.46M Buy
40,076
+15,022
+60% +$1.16M 0.07% 212
2020
Q3
$1.76M Buy
+25,054
New +$1.78M 0.05% 290
2020
Q2
Sell
-38,720
Closed -$1.79M 1541
2020
Q1
$1.79M Sell
38,720
-13,336
-26% -$743K 0.12% 168
2019
Q4
$3.21M Buy
52,056
+36,463
+234% +$1.95M 0.14% 123
2019
Q3
$663K Buy
15,593
+10,513
+207% +$498K 0.03% 533
2019
Q2
$263K Buy
+5,080
New +$253K 0.02% 573
2018
Q3
Sell
-4,516
Closed -$258K 408
2018
Q2
$258K Buy
+4,516
New +$246K 0.09% 166
2017
Q1
Sell
-10,360
Closed -$413K 125
2016
Q4
$413K Buy
+10,360
New +$442K 0.53% 29
2016
Q3
Sell
-9,694
Closed -$376K 117
2016
Q2
$376K Buy
+9,694
New +$418K 0.23% 58

Other funds holding BIB

HRT Financial's BIB Position: Q1 2022 in Review

HRT Financial sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2022, closing a stake of 6,616 shares — an estimated $536K sold.

HRT Financial first reported a position in BIB in Q2 2016 and held it in 12 quarters. The position peaked at $3.46M in Q4 2020. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2022.

  • HRT Financial reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2022 after selling out during the quarter.
  • HRT Financial sold 6,616 ProShares Ultra NASDAQ Biotechnology shares in Q1 2022, an estimated $536K.
  • HRT Financial first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2016 and held it in 12 quarters.
  • HRT Financial's ProShares Ultra NASDAQ Biotechnology position peaked at $3.46M in Q4 2020.
  • 28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.